Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib

Biologics: Targets and Therapy

Volumn 7, Issue 1, 2013, Pages 13-32

  Nooka, Ajay ^a   Gleason, Charise ^a   Casbourne, Daniela ^a   Lonial, Sagar ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Carfilzomib; Epoxyketone; Myeloma; Proteasome inhibitor; Second generation

Indexed keywords

BORTEZOMIB; CARFILZOMIB; CYCLOPHOSPHAMIDE; CYTARABINE; DELANZOMIB; DEXAMETHASONE; ENTINOSTAT; HISTONE DEACETYLASE INHIBITOR; IDARUBICIN; IXAZOMIB CITRATE; LENALIDOMIDE; OPROZOMIB; PANOBINOSTAT; POMALIDOMIDE; PROTEASOME INHIBITOR; RITUXIMAB; SALINOSPORAMIDE A; THALIDOMIDE; VALPROIC ACID; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; BINDING AFFINITY; CANCER RECURRENCE; CANCER RESISTANCE; CHEMOTHERAPY INDUCED EMESIS; CHRONIC LYMPHATIC LEUKEMIA; CONSTIPATION; COUGHING; CYTOGENETICS; DIARRHEA; DISTRIBUTION VOLUME; DOSE RESPONSE; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FEVER; DRUG HALF LIFE; DRUG POTENTIATION; DRUG SAFETY; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG TOLERABILITY; DYSPNEA; FATIGUE; GERIATRIC PATIENT; HUMAN; HYPERGLYCEMIA; HYPOXIA; IC 50; KIDNEY FAILURE; LIPOSARCOMA; LUNG NON SMALL CELL CANCER; LYMPHOMA; MANTLE CELL LYMPHOMA; MELANOMA; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYELOMA CELL; NAUSEA; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PANCREAS CANCER; PERIPHERAL NEUROPATHY; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROSTATE CANCER; REVIEW; SIDE EFFECT; SOLID TUMOR; THROMBOCYTOPENIA; TREATMENT DURATION; TUMOR XENOGRAFT; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WALDENSTROEM MACROGLOBULINEMIA;

EID: 84873345627     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: 10.2147/BTT.S24580     Document Type: Review

References (117)

1. Jung T, Catalgol B, Grune T. The proteasomal system. Mol Aspects Med. 2009;30(4):191-296.
2. Rabl J, Smith DM, Yu Y, Chang S-C, Goldberg AL, Cheng Y. Mechanism of gate opening in the 20S proteasome by the proteasomal ATPases. Mol Cell. 2008;30(3):360-368.
3. Liu C-W, Li X, Thompson D, et al. ATP binding and ATP hydrolysis play distinct roles in the function of 26S proteasome. Mol Cell. 2006;24(1):39-50.
4. Braun BC, Glickman M, Kraft R, et al. The base of the proteasome regulatory particle exhibits chaperone-like activity. Nat Cell Biol. 1999;1(4):221-226.
5. Orlowski M, Wilk S. Catalytic activities of the 20S proteasome: a multicatalytic proteinase complex. Arch Biochem Biophys. 2000;383(1):1-16.
6. Keith DW. Ubiquitination and deubiquitination: targeting of proteins for degradation by the proteasome. Semin Cell Dev Biol. 2000;11(3):141-148.
7. Dorsey BD, Iqbal M, Chatterjee S, et al. Discovery of a potent, selective, and orally Active proteasome inhibitor for the treatment of cancer. J Med Chem. 2008;51(4):1068-1072.
8. Kisselev AF, Callard A, Goldberg AL. Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate. J Biol Chem. 2006;281(13):8582-8590.
9. Griffin TA, Nandi D, Cruz M, et al. Immunoproteasome assembly: cooperative incorporation of interferon γ (IFN-γ)-inducible subunits. J Exp Med. 1998;187(1):97-104.
10. Dick LR, Fleming PE. Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy. Drug Discov Today. 2010;15(5-6):243-249.
11. Kane RC, Farrell AT, Sridhara R, Pazdur R. United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy. Clin Cancer Res. 2006;12(10):2955-2960.
12. Richardson PG, Weller E, Lonial S, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood. 2010;116(5):679-686.
13. Cavo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised Phase 3study. Lancet. 2010;376(9758):2075-2085.
14. Nooka AK, Kaufman JL, Behera M, et al. The improved efficacy of bortezomib containing induction regimens (BCIR) versus nonbortezomib containing induction regimens (NBCIR) in transplant-eligible patients with multiple myeloma (MM): meta-analysis of Phase III randomized controlled trials (RCTs). ASH Annual Meeting Abstracts. 2011;118(21):3994.
15. Bringhen S, Larocca A, Rossi D, et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood. 2010;116(23):4745-4753.
16. Argyriou AA, Iconomou G, Kalofonos HP. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood. 2008;112(5):1593-1599.
17. Windebank AJ, Grisold W. Chemotherapy-induced neuropathy. J Peripher Nerv Syst. 2008;13(1):27-46.
18. Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, Phase 3, non-inferiority study. Lancet Oncol. 2011;12(5):431-440.
19. Oerlemans R, Franke NE, Assaraf YG, et al. Molecular basis of bortezomib resistance: proteasome subunit β5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood. 2008;112(6):2489-2499.
20. Kumar S, Rajkumar SV. Many facets of bortezomib resistance/susceptibility. Blood. 2008;112(6):2177-2178.
21. Kupperman E, Lee EC, Cao Y, et al. Evaluation of the proteasome inhibitor MLN9708in preclinical models of human cancer. Cancer Res. 2010;70(5):1970-1980.
22. Richardson PG, Baz R, Wang L, et al. Investigational agent MLN9708, an oral proteasome inhibitor in patients (Pts) with relapsed and/or refractory multiple myeloma (MM): results from the expansion cohorts of a Phase 1 dose-escalation study. ASH Annual Meeting Abstracts. 2011;118(21):301.
23. Kumar S, Bensinger WI, Reeder CB, et al. Weekly dosing of the investigational oral proteasome inhibitor MLN9708in patients with relapsed and/or refractory multiple myeloma: results from a Phase 1 dose-escalation study. ASH Annual Meeting Abstracts. 2011;118(21):816.
24. Berdeja JG, Richardson PG, Lonial S, et al. Phase 1/2study of oral MLN9708, a novel, investigational proteasome inhibitor in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma (MM). ASH Annual Meeting Abstracts. 2011;118(21):479.
25. Durie BGM, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467-1473.
26. Sanchez E, Li M, Steinberg JA, et al. Oral dosing of the novel proteasome inhibitor CEP-18770 shows marked anti-myeloma effects in SCID-Hu models of multiple myeloma. ASH Annual Meeting Abstracts. 2009;114(22):1840.
27. Piva R, Ruggeri B, Williams M, et al. CEP-18770: a novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. Blood. 2008;111(5):2765-2775.
28. NIH. Phase I study of the proteosome inhibitor CEP 18770in patients with solid tumours or non-Hodgkin's lymphomas. In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2007. Available from: http://clinicaltrials.gov/show/NCT00572637. Accessed February 26, 2012.
29. NIH. Study to determine the maximum tolerated dose and evaluate the efficacy and safety of CEP-18770in patients with relapsed multiple myeloma refractory to the most recent therapy. In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2010. Available from: http://clinicaltrials.gov/show/NCT01023880. Accessed February 26, 2012.
30. NIH. CEP-18770in combination with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma. In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2011. Available from: http://clinicaltrials.gov/show/NCT01348919. Accessed February 26, 2012.
31. Sanchez E, Nichols CM, Lam AC, et al. Efficacy and tolerability of CEP-18770in combination with dexamethasone and lenalidomide using a SCID-Hu model of multiple myeloma (MM). ASH Annual Meeting Abstracts. November 18, 2011;118(21):2946.
32. Chauhan D, Hideshima T, Anderson KC. A novel proteasome inhibitor NPI-0052 as an anticancer therapy. Br J Cancer. 2006;95:961-965.
33. Singh AV, Lloyd GK, Palladino MA, Chauhan D, Anderson KC. Pharmacodynamic and efficacy studies of a novel proteasome NPI-0052in human plasmacytoma Xenograft Mouse Model. ASH Annual Meeting Abstracts. 2008;112(11):3665.
34. Chauhan D, Catley L, Li G, et al. A novel orally active inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell. 2005;8(5):407-419.
35. Richardson P, Hofmeister C, Jakubowiak A, et al. Phase 1 clinical trial of the novel structure proteasome inhibitor NPI-0052in patients with relapsed and relapsed/refractory multiple myeloma (MM). ASH Annual Meeting Abstracts. 2009;114(22):431.
36. Chauhan D, Singh AV, Ciccarelli B, Richardson PG, Palladino MA, Anderson KC. Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma. Blood. 2010;115(4):834-845.
37. NIH. Phase 1 clinical trial of NPI-0052in patients with advanced solid tumor malignancies or refractory lymphoma. In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2006. Available from: http://clinicaltrials.gov/show/NCT00396864. Accessed February 26, 2012.
38. NIH. Phase 1 clinical trial of NPI-0052in patients with relapsed or relapsed/refractory multiple myeloma. In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2007. Available from: http://clinicaltrials.gov/show/NCT00461045. Accessed February 26, 2012.
39. NIH. Proteasome inhibitor NPI-0052 and vorinostat in patients with non-small cell lung cancer, pancreatic cancer, melanoma or lymphoma. In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2008. Available from: http://clinicaltrials.gov/show/NCT00667082. Accessed February 26, 2012.
40. Chauhan D, Singh AV, Aujay M, et al. A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma. Blood. 2010;116(23):4906-4915.
41. Papadopoulos K, Mendelson D, Tolcher A, et al. A Phase I, open-label, dose-escalation study of the novel oral proteasome inhibitor (PI) ONX 0912 in patients with advanced refractory or recurrent solid tumors. J Clin Oncol. 2011;Suppl 29:Abstr 3075.
42. NIH. Open-label study of the safety and activity of ONX 0912in patients with hematological malignancies. In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2011. Avilable from: http://clinicaltrials.gov/show/NCT01416428. Accessed February 27, 2012.
43. Elofsson M, Splittgerber U, Myung J, Mohan R, Crews CM. Towards subunit-specific proteasome inhibitors: synthesis and evaluation of peptide α′, β′-epoxyketones. Chemistry and Biology. 1999;6(11):811-822.
44. Dikic I, Crosetto N, Calatroni S, Bernasconi P. Targeting ubiquitin in cancers. Eur J Cancer. 2006;42(18):3095-3102.
45. Arastu-Kapur S, Ball AJ, Anderl JL, Bennett MK, Kirk CJ. Neurodegeneration induced by bortezomib exposure in vitro occurs via proteasome independent mechanisms. ASH Annual Meeting Abstracts. 2009;114(22):2859.
46. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006;5(9):769-784.
47. Fuchs O, Provaznikova D, Marinov I, Kuzelova K, Spicka I. Antiproliferative and proapoptotic effects of proteasome inhibitors and their combination with histone deacetylase inhibitors on leukemia cells. Cardiovasc Hematol Disord Drug Targets. 2009;9(1):62-77.
48. Hideshima T, Richardson PG, Anderson KC. Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma. Mol Cancer Ther. 2011;10(11):2034-2042.
49. Mitsiades CS, Mitsiades NS, McMullan CJ, et al. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci U S A. 2004;101(2):540-545.
50. Zhang QL, Wang L, Zhang YW, et al. The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis. Leukemia. 2009;23(8):1507-1514.
51. Badros A, Burger AM, Philip S, et al. Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. Clin Cancer Res. 2009;15(16):5250-5257.
52. Rao R, Fiskus W, Yang Y, et al. Co-treatment with panobinostat enhances bortezomib-induced unfolded protein response, endoplasmic reticulum stress and apoptosis of human mantle cell lymphoma cells. ASH Annual Meeting Abstracts. 2008;112(11):887.
53. Dasmahapatra G, Lembersky D, Son MP, et al. Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo. Mol Cancer Ther. 2011;10(9):1686-1697.
54. Dasmahapatra G, Lembersky D, Kramer L, et al. The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo. Blood. 2010;115(22):4478-4487.
55. Rao R, Fiskus W, Balusu R, et al. Treatment with histone deacetylase 6-specific inhibitor WT-161 disrupts hsp90 function, abrogates aggresome formation and sensitizes human mantle cell lymphoma cells to lethal ER stress induced by proteasome inhibitor carfilzomib. ASH Annual Meeting Abstracts. 2010;116(21):2856.
56. NIH. Study of carfilzomib and vorinostat for relapsed or refractory lymphoma. In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2011. Available from: http://clinicaltrials.gov/show/NCT01276717. Accessed February 27, 2012.
57. NIH. A study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in relapsed and/or refractory multiple myeloma (QUAD). In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2011. Available from: http://clinicaltrials.gov/show/NCT01297764. Accessed February 27, 2012.
58. NIH. Carfilzomib plus panobinostat in relapsed/refractory multiple myeloma (MM). In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2011. Available from: http://clinicaltrials.gov/show/NCT01301807. Accessed February 27, 2012.
59. NIH. Study of the combination of panobinostat and carfilzomib in patients qith relapsed/refractory multiple myeloma. In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2011. Available from: http://clinicaltrials.gov/show/NCT01496118. Accessed February 27, 2012.
60. Stapnes C, Døskeland AP, Hatfield K, et al. The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells. Br J Haematol. 2007;136(6):814-828.
61. Niewerth D, Franke N, Jansen G, et al. Sensitivity of pediatric acute leukemia cells to bortezomib and epoxyketone-based proteasome inhibitors: correlations with proteasome subunit expression. ASH Annual Meeting Abstracts. 2011;118(21):1513.
62. Gupta SV, Hertlein EK, Woyach JA, et al. The novel proteasome inhibitor carfilzomib functions independently of p53 to induce potent cytotoxicity in primary chronic lymphocytic leukemia cells and a defective NF-{kappa}B response. ASH Annual Meeting Abstracts. 2011;118(21):3510.
63. Zhang L, Qian J, Ou Z, et al. Carfilzomib, an irreversible proteasome inhibitor induces long-term growth inhibition of mantle cell lymphoma in vivo. ASH Annual Meeting Abstracts. 2011;118(21):3740.
64. Gu J, Hernandez-Ilizaliturri FJ, Kaufman GP, Mavis C, Czuczman MS. Carfilzomib (CFZ): a novel proteasome inhibitor that induces cell cycle arrest and cell death in rituximab-chemotherapy resistant lymphoma and potentiates the anti-tumor activity of chemotherapeutic agents. ASH Annual Meeting Abstracts. 2010;116(21):4908.
65. Gu J, Czuczman NM, Kaufman GP, Mavis C, Hernandez-Ilizaliturri FJ, Czuczman MS. The novel proteasome inhibitor carfilzomib (CFZ) potentiates the anti-tumor activity of chemotherapeutic agents in rituximab-chemotherapy resistant lymphoma through inducing G2/M cell cycle arrest and cell death. ASH Annual Meeting Abstracts. 2011;118(21):4970.
66. Pham LV, Tamayo AT, Li C, Lee J, Fayad L, Ford RJ. Chemo-resistance in diffuse large cell lymphoma: novel drug combinations targeting NFAT/NF-Kb growth/survival/chemo-resistance signaling pathways in validated novel experimental systems. ASH Annual Meeting Abstracts. 2011;118(21):1428.
67. Sacco A, Aujay M, Morgan B, et al. Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom's macroglobulinemia. Clin Cancer Res. 2011;17(7):1753-1764.
68. Zhou H-J, Aujay MA, Bennett MK, et al. Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047). J Med Chem. 2009;52(9):3028-3038.
69. Arastu-Kapur S, Anderl JL, Kraus M, et al. Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events. Clin Cancer Res. 2011;17(9):2734-2743.
70. Kuhn DJ, Chen Q, Voorhees PM, et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood. 2007;110(9):3281-3290.
71. Demo SD, Kirk CJ, Aujay MA, et al. Antitumora of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res. 2007;67(13):6383-6391.
72. Berkers CR, Verdoes M, Lichtman E, et al. Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib. Nat Meth. 2005;2(5):357-362.
73. Kraus M, Florea B, Bader J, et al. Selective inhibition of the proteasome's {beta}2 catalytic subunit alone does not induce cytotoxicity, but resensitizes bortezomib-refractory myeloma cells for bortezomib treatment. ASH Annual Meeting Abstracts. 2011;118(21):2915.
74. Parlati F, Lee SJ, Aujay M, et al. Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome. Blood. 2009;114(16):3439-3447.
75. Lee SJ, Woo TM, Arastu-Kapur S, Wong AF, Renau TE, Kirk CJ. Potent inhibition of multiple proteasome subunits by carfilzomib in multiple myeloma and solid tumor patients. ASH Annual Meeting Abstracts. 2011;118(21):5068.
76. Papadopoulos KP, Lee P, Singhal S, et al. A phase 1b/2study of prolonged infusion carfilzomib in patients with relapsed and/or refractory (R/R) multiple myeloma: updated efficacy and tolerability from the completed 20/56mg/m2 expansion cohort of PX-171-007. ASH Annual Meeting Abstracts. 2011;118(21):2930.
77. Yang J, Wang Z, Fang Y, et al. Pharmacokinetics, pharmacodynamics, metabolism, distribution, and excretion of carfilzomib in rats. Drug Metab Dispos. 2011;39(10):1873-1882.
78. Papadopoulos K, Mendelson D, Tolcher A, et al. A Phase I, open-label, dose-escalation study of the novel oral proteasome inhibitor (PI) ONX 0912 in patients with advanced refractory or recurrent solid tumors. J Clin Oncol. 2011;Suppl 29:Abstr 3075.
79. O'Connor OA, Stewart AK, Vallone M, et al. A Phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. Clin Cancer Res. 2009;15(22):7085-7091.
80. Orlowski RZ, Stinchcombe TE, Mitchell BS, et al. Phase I trial of the proteasome inhibitor PS-341in patients with refractory hematologic malignancies. J Clin Oncol. 2002;20(22):4420-4427.
81. Lonial S, Waller EK, Richardson PG, et al. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood. 2005;106(12):3777-3784.
82. Alsina M, Trudel S, Vallone M, Molineaux C, Kunkel L, Goy A. Phase 1single agent antitumor activity of twice weekly consecutive day dosing of the proteasome inhibitor carfilzomib (PR-171) in hematologic malignancies. ASH Annual Meeting Abstracts. 2007;110(11):411.
83. Jagannath S, Vij R, Stewart K, et al. Final results of PX-171-003-A0, part 1 of an open-label, single-arm, Phase II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM). J Clin Oncol. 2009;27(Suppl 15s):Abstr 8504.
84. Vij R, Kaufman JL, Jakubowiak AJ, et al. Final results from the bortezomib-naive group of PX-171-004, a Phase 2study of single-agent carfilzomib in patients with relapsed and/or refractory MM. ASH Annual Meeting Abstracts. 2011;118(21):813.
85. Siegel D, Wang L, Orlowski RZ, et al. PX-171-004, An ongoing open-label, Phase II study of single-agent carfilzomib (CFZ) in patients with relapsed or refractory myeloma (MM); updated results from the bortezomib-treated cohort. ASH Annual Meeting Abstracts. 2009;114(22):303.
86. Vij R, Siegel D, Kaufman J, et al. Results of an ongoing open-label, Phase II study of carfilzomib in patients with relapsed and/or refractory multiple myeloma (R/R MM). J Clin Oncol. 2010;28(Suppl 15s):Abstr 8000.
87. Badros A, Vij R, Martin T, et al. Phase II study of carfilzomib in patients with relapsed/refractory multiple myeloma and renal insufficiency. J Clin Oncol. 2010;28(Suppl 15s):Abstr 8128.
88. Wang M, Bensinger W, Martin T, et al. Interim results from PX-171-006, a Phase (Ph) II multicenter dose-expansion study of carfilzomib (CFZ), lenalidomide (LEN), and low-dose dexamethasone (loDex) in relapsed and/or refractory multiple myeloma (R/R MM). J Clin Oncol. 2011;(Suppl 29):Abstr 8025.
89. Moreau P, Palumbo A, Stewart A, et al. A randomized, multicenter, Phase (Ph) III study comparing carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (Dex) to LEN and Dex in patients (Pts) with relapsed multiple myeloma (MM). J Clin Oncol. 2011;(Suppl 29): abstr TPS225.
90. Jakubowiak AJ, Dytfeld D, Jagannath S, et al. Final results of a frontline phase 1/2 dtudy of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) in multiple myeloma (MM). ASH Annual Meeting Abstracts. 2011;118(21):631.
91. Sonneveld P, Hacker E, Zweegman S, et al. Carfilzomib combined with thalidomide and dexamethasone (CARTHADEX) as induction treatment prior to high-dose melphalan (HDM) in newly diagnosed patients with multiple myeloma (MM). a trial of the European Myeloma Network EMN. ASH Annual Meeting Abstracts. 2011;118(21):633.
92. Singhal S, Siegel DS, Martin T, et al. Integrated safety from Phase 2studies of monotherapy carfilzomib in patients with relapsed and refractory multiple myeloma (MM): an updated analysis. ASH Annual Meeting Abstracts. 2011;118(21):1876.
93. NIH. A study of carfilzomib maintenance therapy in subjects previously enrolled in carfilzomib treatment protocols. In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2009. Available from: http://clinicaltrials.gov/show/NCT00884312. Accessed February 27, 2012.
94. Martin T, Singhal SB, Vij R, et al. Baseline peripheral neuropathy does not impact the efficacy and tolerability of the novel proteasome inhibitor carfilzomib (CFZ): results of a subset analysis of a Phase 2 trial in patients with relapsed and refractory multiple myeloma (R/R MM). ASH Annual Meeting Abstracts. 2010;116(21):3031.
95. Jakubowaik AJ, Siegel DS, Singhal S, et al. Unfavorable cytogenetic characteristics do not adversely impact response rates in patients with relapsed and/or refractory multiple myeloma treated with single-agent carfilzomib on the 003 (A1) study. ASH Annual Meeting Abstracts. 2011;118(21):1875.
96. Badros AZ, Vij R, Martin T, et al. Phase I study of carfilzomib in patients (Pts) with relapsed and refractory multiple myeloma (MM) and varying degrees of renal insufficiency. ASH Annual Meeting Abstracts. 2009;114(22):3877.
97. Squifflet P, Michiels S, Siegel DS, Vij R, Ro S, Buyse ME. Multivariate modelling reveals evidence of a dose-response relationship in Phase 2 studies of single-agent carfilzomib. ASH Annual Meeting Abstracts. 2011;118(21):1877.
98. Wang L, Siegel DS, Jakubowiak AJ, et al. The speed of response to single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma: an exploratory analysis of results from 2multicenter Phase 2 clinical yrials. ASH Annual Meeting Abstracts. 2011;118(21):3969.
99. Jagannath S, Vij R, Kaufman JL, et al. Long-term treatment and tolerability of the novel proteasome inhibitor carfilzomib (CFZ) in patients with relapsed and/or refractory multiple myeloma (R/R MM). ASH Annual Meeting Abstracts. 2010;116(21):1953.
100. Siegel D, Martin T, Wang M, et al. PX-171-003-A1, an open-label, single-arm, Phase (Ph) II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (R/R MM): long-term follow-up and subgroup analysis. J Clin Oncol. 2011;Suppl 29:Abstr 8027.
101. NIH. Carfilzomib in patients with relapsed acute myeloid or acute lymphoblastic leukemia (AML ALL). In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2010. Available from: http:/clinicaltrials.gov/show/NCT01137747. Accessed February 27, 2012.
102. NIH. Study of carfilzomib in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) or prolymphocytic leukemia (PLL). In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2010. Available from: http:/clinicaltrials.gov/show/NCT01212380. Accessed February 27, 2012.
103. NIH. Carfilzomib in treating patients with relapsed or refractory T-cell lymphoma. In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2011. Available from: http:/clinicaltrials.gov/show/NCT01336920. Accessed February 26, 2012.
104. NIH. Phase 1b multicenter study of carfilzomib with lenalidomide and dexamethasone in relapsed multiple myeloma. In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2008. Available from http:/clinicaltrials.gov/show/NCT00603447. Accessed February 27, 2012.
105. NIH. A safety study of carfilzomib and pomalidomide with dexamethasone in patients with relapsed or refractory multiple myeloma. In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2011. Available from: http://clinicaltrials.gov/show/NCT01464034. Accessed February 27, 2012.
106. NIH. Study of carfilzomib for multiple myeloma patients who are relapsed/refractory to bortezomib-containing treatments. In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2011. Available from: http://clinicaltrials.gov/show/NCT01365559. Accessed February 27, 2012.
107. NIH. Trial of carfilzomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma (CARMYSAP). In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2010. Available from: http://clinicaltrials.gov/show/NCT01279694. Accessed February 27, 2012.
108. NIH. Carfilzomib and pegylated liposomal doxorubicin hydrochloride in treating patients with relapsed or refractory multiple myeloma. In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2011. Available from: http://clinicaltrials.gov/show/NCT01246063. Accessed February 27, 2012.
109. NIH. Arry-520 + carfilzomib for multiple myeloma (MM). In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2012. Available from: http://clinicaltrials.gov/show/NCT01372540. Accessed February 27, 2012.
110. NIH. Cyclophosphamide, carfilzomib, thalidomide, and dexamethasone in treating patients with newly diagnosed active multiple myeloma. In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2010. Available from: http://clinical trials.gov/show/NCT01057225. Accessed February 27, 2012.
111. NIH. Carfilzomib and lenalidomide with dexamethasone combination in newly diagnosed, previously untreated multiple myeloma. In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2009. Available from: http://clinicaltrials.gov/show/NCT01029054. Accessed February 27, 2012.
112. NIH. Carfilzomib, rituximab and dexamethasone in Waldenstrom's macroglobulinemia (CaRD). In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2011. Available from: http://clinicaltrials.gov/show/NCT01470196. Accessed February 27, 2012.
113. NIH. Infusional carfilzomib in patients with relapsed or refractory multiple myeloma. In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2011. Available from: http://clinicaltrials.gov/show/NCT01351623. Accessed February 27, 2012.
114. NIH. Carfilzomib, cyclophosphamide and dexamethasone in newly diagnosed multiple myeloma patients (CCD). In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2011. Available from: http://clinicaltrials.gov/show/NCT01346787. Accessed February 27, 2012.
115. NIH. Carfilzomib, lenalidomide, and dexamethasone in new multiple myeloma patients. In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2011. Available from: http://clinicaltrials.gov/show/NCT01402284. Accessed February 27, 2012.
116. NIH. Phase 3study comparing carfilzomib, lenalidomide, and dexamethasone (CRd) versus lenalidomide and dexamethasone (Rd) in subjects with relapsed multiple myeloma. In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2010. Available from: http://clinicaltrials.gov/show/NCT01080391. Accessed February 27, 2012.
117. NIH. A study of carfilzomib vs best supportive care in subjects with relapsed and refractory multiple myeloma (FOCUS). In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2010. Avilable from: http://clinicaltrials.gov/show/NCT01302392. Accessed February 27, 2012.